A mixed 
liposome pharmaceutical formulation with multilamellar vesicles, comprises a proteinic pharmaceutical agent, water, an 
alkali metal lauryl sulphate in a concentration of from 1 to 10 wt. / wt. %, at least one membrane-mimetic 
amphiphile and at least one 
phospholipid. The membrane-mimetic 
amphiphile is 
hyaluronic acid, pharmaceutically acceptable salts of 
hyaluronic acid, lauramidopropyl betain, lauramide monoisopropanolamide, 
sodium cocoamphopropionate, bishydroxypropyl dihydroxypropyl stearammonium 
chloride, polyoxyethylene dihydroxypropyl stearammonium 
chloride, dioctadecyldimethylammonium 
chloride, sulphosuccinates, stearamide DEA, gamma-
linoleic acid, 
borage oil, 
evening of primrose oil, monoolein, 
sodium tauro dihydro fusidate, 
fusidic acid, 
alkali metal isostearyl lactylates, 
alkaline earth metal isostearyl lactylates, panthenyl triacetate, cocamidopropyl phosphatidyl PG-diammonium chloride, stearamidopropyl phosphatidyl PG-diammonium chloride, 
borage amidopropyl phosphatidyl PG-diammonium chloride, 
borage amidopropyl 
phosphatidylcholine, polysiloxy pyrrolidone linoleyl 
phospholipid, trihydroxy-oxo-cholanylglycine and 
alkali metal salts thereof, and octylphenoxypolythoxyethanol, polydecanol X-lauryl 
ether, polydecanol X-
oleyl ether, wherein X is from 9 to 20, or combinations thereof. The 
phospholipid is phospolipid GLA, 
phosphatidyl serine, 
phosphatidylethanolamine, inositolphosphatides, dioleoylphosphatidylethanolamine, 
sphingomyelin, ceramides, cephalin, 
triolein, 
lecithin, saturated 
lecithin and lysolecithin, or a combination thereof. The amount of each membrane mimetic 
amphiphile and phospholipid is present 1 to 10 wt. / wt. % of the total formulation, and the total concentration of membrane mimetic amphiphiles and phospholipids is less than 50 wt. / wt. % of the formulation.